Completed PHASE1 INTERVENTIONAL 3-arm NCT02998437

Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole (DDI)

A Randomized, Open-label, Parallel-design Study to Evaluate Pharmacokinetic Drug Interactions and Safety After Coadministration of Clarithromycin, Amoxicillin and Ilaprazole

Sponsor: Il-Yang Pharm. Co., Ltd.

Conditions Drug Interaction Potentiation

Interventions Amoxicillin 500 Mg Clarithromycin 500mg Ilaprazole 10mg

Updated 7 times since 2017 Last updated: Jan 24, 2017 Started: Dec 31, 2016 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Drug Interaction Potentiation and is currently completed. Il-Yang Pharm. Co., Ltd. leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE1

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Il-Yang Pharm. Co., Ltd.
Severance Hospital

Data source: Il-Yang Pharm. Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea